Clinical Trials Logo

Clinical Trial Summary

CC-42344 Phase 1 study with single-ascending dose (SAD) and multiple-ascending dose (MAD) parts.


Clinical Trial Description

This study is testing the safety, tolerability, and pharmacokinetics (PK, the amount of study drug in the blood) of a new drug called CC-42344. Up to 56 healthy men or women aged between 18-55 will be enrolled in this study in two parts. Part 1 will involve a single-ascending (increasing) dose (SAD) where 32 participants (4 groups of 8) will be assigned randomly to receive a single oral dose of the study drug or placebo. The placebo will look the same as the study drug but will not contain any medicine. Part 2: will involve a multiple-ascending dose (MAD) where 24 participants (3 groups of 8) will be randomised to receive an oral dose of study drug or placebo given once a day for 14 days. The placebo will look the same as the study drug but will not contain any medicine. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05202379
Study type Interventional
Source Cocrystal Pharma, Inc.
Contact Sam Lee, PhD
Phone (425) 750-7208
Email [email protected]
Status Recruiting
Phase Phase 1
Start date February 11, 2022
Completion date September 2022

See also
  Status Clinical Trial Phase
Completed NCT03999554 - Safety and Immunogenicity of the Bris10 M2SR and Sing2016 M2SR H3N2 Monovalent Influenza Vaccines Phase 1
Completed NCT02487173 - Validation of the Respirio Flu Test for the Rapid Identification of Influenza A/B N/A
Completed NCT01701752 - Influenza A Vaccine (FP-01.1) Formulated With and Without Adjuvant, in the Presence or Absence of a Single Administration of a Trivalent Inactivated Influenza Virus Vaccine in Older Adults Phase 1
Enrolling by invitation NCT03207152 - Biomarkers Predicting Infectivity in an Experimental Human Influenza Model Phase 1
Not yet recruiting NCT00987012 - The Influence of Fortified Pomegranate Juice (Punica Granatum) on Seasonal Influenza and Swine Flu Patients N/A
Completed NCT03651544 - The Study of the Safety, Reactogenicity and Immunogenicity of the GamFluVac Phase 1
Completed NCT02623322 - A Study of MHAA4549A as Monotherapy for Acute Uncomplicated Seasonal Influenza A in Otherwise Healthy Adults Phase 2
Completed NCT03196661 - Preliminary Study on Safety and Immunogenicity of Influenza A (H7N9) Vaccine in the Population Phase 1
Recruiting NCT05163730 - Clinical Evaluation of the Panbio™ COVID-19/ Flu A&B Rapid Panel N/A
Recruiting NCT05354115 - Sample Collection for Evaluation of the Panbio™ COVID-19/ Flu A&B Rapid Panel. N/A
Completed NCT02014870 - Safety and Reactogenicity of a H1N1 Influenza Challenge Virus in Healthy Volunteers Phase 1
Completed NCT02767414 - Validation of the Ellume® Respirio Flu Test and the Ellume® eLab Flu Test for the Rapid Identification of Influenza A/B N/A
Completed NCT00922259 - Safety and Immunogenicity of Live Influenza A Vaccine for Avian Influenza H7N7 Phase 1
Recruiting NCT03238612 - Flufenamic Acid for Hospitalised Influenza Infection Phase 2
Active, not recruiting NCT04653727 - Effects of Integrative Medicine on Infectious Respiratory Diseases Including COVID-19
Recruiting NCT05268939 - Performance Evaluation of the LumiraDx SARS-CoV-2 & FLU A/B and SARS-CoV-2 & RSV Tests for Aid in the Assessment of COVID-19 N/A
Terminated NCT03376321 - A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Hospitalized Participants With Influenza A Infection Phase 3
Completed NCT03040141 - Study to Evaluate the Efficacy and Safety of IV VIS410 Plus Oseltamivir Versus Oseltamivir Alone in Hospitalized Adults With Influenza A Infection Requiring Oxygen Support Phase 2
Terminated NCT03381196 - A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Non-Hospitalized Participants With Influenza A Infection Who Are at Risk of Developing Complications Phase 3
Completed NCT02287467 - Evaluating the Safety and Efficacy of Anti-Influenza Intravenous Hyperimmune Immunoglobulin (IVIG) in Adults Hospitalized With Influenza Phase 3